What is Genfit?
Founded in 1999 and headquartered in Loos Hauts-de-France, Genfit is a bio-pharmaceutical entity dedicated to the development of innovative therapeutic and diagnostic solutions. The company's primary focus lies in addressing unmet needs within the fields of metabolic and inflammatory diseases. Genfit's strategic approach involves leveraging its scientific expertise to create novel treatments and diagnostic tools aimed at improving patient outcomes and quality of life. The company's commitment to research and development positions it as a key player in the biopharmaceutical landscape, striving to bring impactful medical advancements to market.
How much funding has Genfit raised?
Genfit has raised a total of $703M across 13 funding rounds:
Share Placement
$15.5M
Share Placement
$5.4M
Share Placement
$22.7M
Share Placement
$36.6M
Share Placement
$48.2M
Debt
$194.5M
Stock Offering
$155.4M
Debt
$13.3M
Debt
$200M
Share Placement (2013): $15.5M, investors not publicly disclosed
Share Placement (2014): $5.4M, investors not publicly disclosed
Share Placement (2014): $22.7M, investors not publicly disclosed
Share Placement (2016): $36.6M, investors not publicly disclosed
Share Placement (2016): $48.2M, investors not publicly disclosed
Debt (2017): $194.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $155.4M, investors not publicly disclosed
Debt (2021): $13.3M led by The French Government
Debt (2025): $200M supported by HealthCare Royalty Management
Key Investors in Genfit
HealthCare Royalty Management
HealthCare Royalty Management is a specialized investment organization focused on providing capital solutions to companies within the biopharmaceutical sector, structured around the acquisition of royalty interests and tailored financing arrangements. The firm primarily targets biopharmaceutical assets that are either in the commercial phase or approaching commercialization, enabling them to invest in products that have already demonstrated clinical value and market potential.
The French Government
The French Government, through its various agencies and initiatives, plays a crucial role in supporting domestic industries, including the vital biopharmaceutical sector. Its involvement often signifies strategic national interests in fostering innovation, job creation, and advancements in public health through targeted financial backing and regulatory support.
OSEO
OSEO, now part of Bpifrance, was a French public agency dedicated to supporting innovation and the growth of small and medium-sized enterprises (SMEs) and mid-cap companies. Its role included providing financial aid, guarantees, and expert advice to help businesses develop and scale their operations, particularly in technology-intensive sectors like biotechnology.
What's next for Genfit?
With the recent infusion of $200M as part of a major strategic investment, Genfit is poised for accelerated expansion and innovation. This substantial capital injection, contributing to its overall funding of $703M, will likely fuel the advancement of its pipeline, enhance its research and development capabilities, and potentially support clinical trial progression and commercialization efforts. The company's strategic focus on metabolic and inflammatory diseases suggests a continued dedication to addressing critical healthcare challenges, with this latest backing enabling a more robust pursuit of its long-term objectives and market penetration.
See full Genfit company page
